Progyny (NASDAQ:PGNY) Updates FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: Progyny set EPS guidance of 1.980–2.09, above the consensus of 1.74, and revenue guidance of $1.4 billion, in line with analyst expectations.
• Shares rose about 2.5% to $19.16 after the update; the company also beat the latest quarter with $0.50 EPS vs. $0.44 expected and $328.5M revenue, and has a market cap near $1.5B with a P/E around 29.5.
• Analyst and ownership backdrop: the stock holds a "Moderate Buy" consensus with a $27.91 target amid mixed price-target revisions, insiders have sold recently, and institutional investors own roughly 94.9% of the shares.

Progyny (NASDAQ:PGNY - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 1.980-2.09 for the period, compared to the consensus earnings per share estimate of 1.740. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. BTIG Research cut their price objective on Progyny from $35.00 to $30.00 and set a "buy" rating for the company in a research note on Thursday, March 5th. Barclays cut their price objective on Progyny from $29.00 to $23.00 and set an "overweight" rating for the company in a research note on Friday, March 20th. Citizens Jmp upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $30.00 price objective for the company in a research note on Tuesday, January 20th. Truist Financial cut their price objective on Progyny from $34.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, March 2nd. Finally, Citigroup upgraded Progyny to an "outperform" rating in a research note on Tuesday, January 20th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $27.91.

Progyny Stock Up 2.5%

Shares of Progyny stock traded up $0.46 on Thursday, hitting $19.16. 1,791,103 shares of the company were exchanged, compared to its average volume of 1,489,923. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 29.48, a price-to-earnings-growth ratio of 1.09 and a beta of 0.91. The company has a 50-day moving average price of $17.91 and a 200 day moving average price of $21.69. Progyny has a 1-year low of $16.10 and a 1-year high of $28.75.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.06. The business had revenue of $328.50 million for the quarter, compared to analysts' expectations of $326.47 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.Progyny has set its FY 2026 guidance at 1.980-2.09 EPS. Research analysts forecast that Progyny will post 1.12 EPS for the current year.

Insider Buying and Selling

In related news, EVP Allison Swartz sold 4,657 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 7,455 shares of company stock valued at $129,515 in the last 90 days. Corporate insiders own 9.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in Progyny during the fourth quarter worth $25,000. Canada Pension Plan Investment Board acquired a new position in Progyny during the second quarter worth $77,000. Quarry LP lifted its stake in Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company's stock worth $77,000 after purchasing an additional 3,427 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Progyny by 203.5% during the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company's stock worth $154,000 after purchasing an additional 4,708 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in Progyny during the fourth quarter worth $203,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.